Topics Damages Pharma in Brief’s 2023 Year in Review and Trends for 2024The Ontario Superior Court dismisses a generic manufacturer’s claim for damages under section 8 of the PM(NOC) RegulationsSupreme Court denies leave to appeal in generic Statute of Monopolies case Intellectual property PMPRB opens consultation to streamline Board hearingsPharma in Brief’s 2025 Year in Review and What to Watch for in 2026Federal Court of Appeal affirms trademark confusion between names of eye medicines Life sciences and healthcare Pharma in Brief’s 2025 Year in Review and What to Watch for in 2026Drug shortages: New requirements proposed for the Food and Drug RegulationsPharma in Brief’s 2024 Year in Review and Trends for 2025 Pharmaceuticals and life sciences PMPRB opens consultation to streamline Board hearingsHealth Canada proposes expediting drug approvals by relying on foreign regulatory decisionsHealth Canada Announces Long-Awaited Clinical Trial Regulations Uncategorized Drug Pricing Update: PMPRB releases final price-review GuidelinesCADTH advisory panel consults on framework for pan-Canadian formularyAmendments to the Federal Courts Rules
